Cathy Tie's Manhattan Project: Gene Editing Embryos in the US

The Manhattan Project: Gene Editing Embryos

• 🚀 Cathy Tie launched the Manhattan Project, a new startup in New York focused on germline gene editing of human embryos.
• 🎯 The project's initial focus is on eliminating single-gene diseases with well-understood correlations, not polygenic traits like IQ or attractiveness.
• 💡 The goal is to save embryos that would otherwise be discarded in IVF, offering more viable options for couples, especially older ones with fewer embryos.
• 🔬 Technology involves CRISPR microinjection and advanced techniques like base editing for precise, safer genetic changes in early-stage embryos.

Navigating Controversy and Regulation

• ✅ Despite the controversial nature of embryo gene editing, Tie reported receiving positive messages from patients with genetic diseases seeking solutions.
• ⚠️ The US has a federal funding ban and a proposed moratorium on germline gene therapy, creating a paradox where safety cannot be proven without research.
• 💰 Gene editing embryos could offer a cost-effective and safer option compared to expensive somatic gene therapies for adults.
• 📈 Tie believes it's crucial to push the conversation forward with transparency, IRB approval, and ethical considerations to advance the science.

The He Jiankui Saga and China Ban

• 🇨🇳 Tie had a brief personal relationship with He Jiankui, the Chinese scientist who controversially gene-edited twins in 2018 and was imprisoned.
• 🚫 After planning to establish a biotech venture in China, Tie was banned from entering the country, an experience she described as unexpected and chaotic.
• 💬 The He Jiankui case, which aimed to prevent HIV, led to widespread scientific condemnation and a crackdown by the Chinese government.

US Leadership in Biotech Innovation

• 🇺🇸 Despite past funding bans, Tie asserts that the US still leads in embryology and genetic modification research, driven by private funding and top talent.
• 🤝 The Manhattan Project is collaborating with 12 leading PIs and bioethicists in the US, aiming to establish ethical and technological leadership.
• 🌍 Tie notes that biotech innovation, unlike software, requires global collaboration, making a fully closed system in any country less effective for progress.

Challenging Biotech Stagnation

• 🧠 Tie criticizes the stagnation in the biotech field, particularly in academia and pharma, where she perceives a lack of bold, risk-taking approaches.
• 🧬 Her personal journey, including starting her first company at 18, was driven by a deep curiosity about DNA and human genetics and a desire to challenge norms.
• 🏀 The discussion touched upon historical "enhancements" like Yao Ming's parents being arranged to produce a tall, athletic offspring, highlighting that genetic influence isn't new.